SM-1 vs. an Active Comparator in A Model of Transient Insomnia

Phase 2

Not yet recruiting

• Conditions: Transient Insomnia
• Interventions: Drug: Active Comparator; Drug: SM-1

• Registration Number: NCT04396327
• Lead Sponsor: Sequential Medicine Ltd

Brief Summary

The purpose of this study is to investigate the effectiveness, safety and tolerability of a combination drug product (SM-1) containing diphenhydramine, zolpidem and lorazepam, in adult participants who sometimes have difficulty in falling asleep or staying asleep, but who do not have chronic insomnia. Participants will receive SM-1 or a combination of diphenhydramine and lorazepam during 2 one-night stays at a sleep center.

Detailed Description

The purpose of this study is to evaluate the effect of a combination drug product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam on total sleep time, and to determine the contribution of zolpidem to the combination, using a 3-hour Phase Advance model of sleep challenge with 8 hours of polysomnographic (PSG) recording. This is a 2-arm, 2-period crossover trial including the 3-drug investigational product and a 2-drug comparator. The 2 arms are: investigational combination product, and a 2-drug comparator containing diphenhydramine and lorazepam but not zolpidem. Participants will be adults who sometimes have difficulty falling asleep or staying asleep, but who are generally healthy and do not have chronic insomnia or sleep apnea.

A total of 14 subjects are planned to enroll in the study. Subjects who qualify for participation will be asked to keep a sleep diary to document their sleep times leading up to their first overnight stay in the sleep center and during the study. Subjects will be asked to spend at least 7.5 hours in bed at a regular bedtime during the study. Qualifying participants also will not anticipate traveling across 3 time zones, be involved in night shift work, or significant disruptions in their sleep schedules during the study. The study requires 2 one-night stays in a sleep center in New York City, for administration of the study treatments and PSG \& EEG measurements. Qualifying subjects will anticipate being able to return to the sleep center, located in Manhattan, for a total of 3 visits, including initial screening and 2 treatment times.

Subjects will receive a follow up phone call from study staff 3 days after final dose of study medication.

During each sleep center visit, subjects will arrive to the sleep center approximately 5 hours prior to their average usual bedtime and will be given their study treatment. Their sleep will be monitored for 8 hours. Each subject will receive both treatments, although the sequence of the 2 treatments will be randomized. Both subjects and study personnel monitoring the subjects will be blinded to the identity of the treatment administered at each visit.

Study Timeline

• Status Verified: 2020-04
• Study First Submitted: 2020-05-08
• Study First Submitted QC: 2020-05-19
• Last Update Submitted: 2020-05-19
• Study First Posted: 2020-05-20
• Last Update Posted: 2020-05-20
• Study Start: 2020-05-27
• Primary Completion: 2020-06-30
• Study Completion: 2020-06-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

1. Age 25 and 55 years
2. Body mass index (BMI) between 19 and 32 kg/m2
3. Report previous history of occasional difficulty falling asleep or staying asleep, but not currently having difficulty sleeping;
4. Regular, habitual bedtime between 21:00 and 24:00, routinely spend at least 7.5 and no more than 9.0 hours in bed nightly and a bedtime that does not vary by more than 2 hours over the course of the week.
5. Good general health
6. Females of childbearing potential must be using an acceptable method of contraception, have a negative serum pregnancy test at screening and have a negative urine pregnancy test before randomization and prior to each Treatment Period.
7. Female subjects who have been surgically sterilized are eligible if they have a negative serum pregnancy test at screening and negative urine pregnancy test at check-in or are post-menopausal or have had a complete hysterectomy;
8. Male subjects must use an acceptable method of contraception during the course of the study and for the 90 days following the last dose of study medication.
9. Obtain signed informed consent
10. Able to stay in the clinical research unit for 1 overnight stay during each treatment period
11. No alcohol on check-in days
12. Refrain from the use of alcohol and from napping on site check-in days
13. A recent history of napping of no more than once per week.

Exclusion Criteria

1. Clinically significant, acute illness within 14 days prior to screening

2. Clinically significant, unstable medical illness;

3. Evidence or history of clinically significant allergic hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic or neurological disease;

4. History of cancer or diabetes;

5. A sitting blood pressure > 140/90 millimeters mercury (mm/Hg) at screening;

6. Heart rate > 100 beats per minute (BPM) at screening;

7. Clinically significant psychiatric illness, including chronic psychiatric illness or the history or presence of any Axis I condition;

8. Subject has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 6 months prior to the start of the screening phase, per the investigator's clinical judgment or based on the C-SSRS

9. History or presence of chronic pain;

10. Lifetime history of seizure disorder or serious head injury;

11. Clinically significant sleep disorder, including chronic insomnia, sleep apnea, narcolepsy, parasomnia, restless leg syndrome or circadian rhythm disorder;

12. Slept in a sleep laboratory at any time prior to Screening.

13. STOP-BANG sleep apnea questionnaire >/= to 3 at Screening;

14. Epworth Sleepiness Scale (ESS) score >10 at screening;

15. Any condition that may affect drug absorption;

16. Travel across more than three time zones or shift worker

17. Any clinically significant abnormal finding on physical examination, vital signs or clinical laboratory tests,

18. History of allergies, or known sensitivity, hypersensitivity, or adverse reaction to any drug similar to diphenhydramine, zolpidem or lorazepam;

19. Pregnant or lactating females;

20. Positive serum or urine pregnancy test

21. Positive urine drug screen

22. Recent history or current evidence of alcohol or drug abuse

23. Regular consumption of "large amounts" of xanthine-containing substances (i.e., [equivalent to approximately 2 - 3 cups of regular coffee] or equivalent amounts of xanthine-containing substances);

24. Usual consumption of more than 14 units of alcohol per week.

25. Use of more than 10 cigarettes or equivalent per day of any product containing nicotine or routinely smokes during sleep period.

26. Stopped smoking or in a smoking cessation program within 90 days of screening;

27. Use of restricted concomitant medications, any prescription drug, OTC medication, grapefruit, grapefruit juice, herbal preparation or food supplement, excluding vitamins, acetaminophen or hormonal contraceptives

28. Exposure to any investigational drug or to diphenhydramine, zolpidem or lorazepam or other drugs of the same pharmaceutical classes within 30 days of screening 30. Positive alcohol or drug test

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Active Comparator: 2-Drug Combination	Active Comparator	50 mg diphenhydramine and 0.5 mg lorazepam
Active Treatment: SM-1 3-Drug Combination	SM-1	3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam

Primary Outcome Measures

Name	Time	Method
Latency to Persistent Sleep (LPS)	8 hours	Time it takes to fall asleep

Secondary Outcome Measures

Name	Time	Method
Subjective Sleep Latency	8 hours	Time it takes to fall asleep in minutes
Wakefulness	8 hours	Time spent awake in minutes
Adverse Events	8 hours	Safety and tolerability assessed in terms of the incidence of AEs

Trial Locations

Locations (1)

Clinilabs Drug Development Corporation; 🇺🇸 New York, New York, United States